Search Results

The world of healthcare is evolving to more predictive care and patients are taking greater control—a trend already emerging around GLP-1 weight loss treatments. As PwC warns, pharma will need to be ready.

While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular obesity drugs that are made by Novo Nordisk and Eli Lilly. In fact, the FDA seems to be signaling that “some level of compounded product is acceptable,” according to BMO Capital Markets.

Sanofi looks to follow a deep history of Big Pharma offloading their consumer healthcare businesses.

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.

Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more Strategic agreement supports TempraMed’s global shift from online B2C to major pharmacy networks and B2B medical payers Distribution to over 2,500 outlets including pharmacy chains, supermarkets, HMOs and independent pharmacies

GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in the forthcoming TrumpRx program.

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending.